G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NEXT STORY
    Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    PREV STORY
    ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2021
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy

    author_avatar
    NASDAQ Market News

    Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia

    author_avatar
    NASDAQ Market News

    Surface Oncology Announces Upcoming Investor Presentations

    CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage ...

    author_avatar
    NASDAQ Market News